MAPT and Alzheimer disease: Afterwards, tau phosphorylation at site 205 (probably modified by GSK3) and at site 202 (modified by GSK3) [16] can occur, correlating with a decrease in gray matter (loss of dendritic arborization and synaptic transmission), yielding the stage of neuronal dysfunction observed in the AD brain [32].